1205MO Updated analysis of DESTINY-Gastric02: A phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable/metastatic gastric/gastroesophageal junction (GEJ) cancer who progressed on or after trastuzumab-containing regimen

Geoffrey Y. Ku, Maria Di Bartolomeo, E.C. Smyth, Ian Chau, H. Park, Salvatore Siena, Sara Lonardi, Z.A. Wainberg, Jaffer A. Ajani, Joseph Chao, F. Barlaskar, Yoshiaki Kawaguchi, A. Qin, Jasmeet Singh, Gudrun Meinhardt, E. Van Cutsem